Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1213/ANE.0000000000007034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cannabis-Responsive Biomarkers: Answering the Call for Critical Appraisal of Medical Cannabis.
Anesth Analg
July 2024
Cannformatics, Inc., San Francisco, California.
A machine learning approach for understanding the metabolomics response of children with autism spectrum disorder to medical cannabis treatment.
Sci Rep
August 2023
Cannformatics, Inc., 3859 Cesar Chavez St, San Francisco, CA, 94131, USA.
Autism spectrum disorder (ASD) is a neurodevelopmental condition impacting behavior, communication, social interaction and learning abilities. Medical cannabis (MC) treatment can reduce clinical symptoms in individuals with ASD. Cannabis-responsive biomarkers are metabolites found in saliva that change in response to MC treatment.
View Article and Find Full Text PDFThe Potential of Salivary Lipid-Based Cannabis-Responsive Biomarkers to Evaluate Medical Cannabis Treatment in Children with Autism Spectrum Disorder.
Cannabis Cannabinoid Res
August 2023
Cannformatics, Inc., San Francisco, California, USA.
Autism spectrum disorder (ASD) is a group of heterogeneous neurodevelopmental conditions affecting social communication and social interaction. Medical cannabis (MC) treatment shows promising results as an approach to reduce behavioral difficulties, as determined mainly by subjective observations. We have recently shown the potential of cannabis-responsive biomarkers detected in saliva of children with ASD to objectively quantify the impact of successful MC treatment using a metabolomics approach.
View Article and Find Full Text PDFCannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.
Cannabis Cannabinoid Res
February 2023
Cannformatics, Inc., San Francisco, California, USA.
Autism spectrum disorder (ASD) is a group of neurodevelopmental conditions that impact behavior, communication, social interaction, and learning abilities. Treatment of ASD with medical cannabis (MC) shows promising results in reducing the severity of certain behavioral aspects. The goals of this observational study are to demonstrate the potential of metabolic biomarkers to (1) objectively determine the impact on metabolites of MC treatment and (2) suggest the metabolic pathways of children with ASD, who respond to MC treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!